FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers

This Medical News article discusses the US Food and Drug Administration’s new boxed warning requirement and investigation of secondary malignancies after CAR T-cell therapy.

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2024-03, Vol.331 (10), p.818-820
Main Author: Suran, Melissa
Format: Article
Language:English
Subjects:
Cell therapy
Lymphocytes T
Malignancy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This Medical News article discusses the US Food and Drug Administration’s new boxed warning requirement and investigation of secondary malignancies after CAR T-cell therapy.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2024.1011